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ABSTRACT 
An endpoint is a primary or secondary outcome used to judge the effectiveness of a treatment; it is a precisely defined variable 
intended to reflect an outcome of interest that is statistically analyzed. An endpoint usually specifies the sort of assessments made, 
the timing of those assessments, the assessment tools used and possibly other details, as applicable, such as how multiple 
assessments within an individual are to be combined. There are different types of endpoints used in clinical trials like primary 
endpoint, secondary endpoint, multiple endpoint and surrogate endpoint. Primary endpoint means the outcome or event that most 
accurately measures the benefit of the therapy or drug being studied and this is the most clinically important endpoint. Seco ndary 
endpoints are related to toxicity and undesired effects of the new therapy to demonstrate additional effects on the disease or 
condition. Multiple endpoints are useful in determining clinical advantage of drug depending on one illness side.  A surrogate endpoint 
is a laboratory measure or a physical sign supposed to be used as a substitute for a clinically meaningful endpoint which in all f airness 
possible to predict clinical benefit. 
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A clinical endpoint is associate degree experiment 
performed by a health care organisation or skilled to 
judge the results of treatment against an impact in a very 
clinical setting. It is a prospective study to spot outcome 
measures that are influenced by the intervention. A 
clinical path is intended to keep up health, stop 
unwellness, or treat pathologic subjects. The safety, 
efficiency, pharmacologic, pharmacokinetic, quality of 
life, health economy, biochemical effects are measured in 
clinical trials. 
There are two different types of clinical trials, 
confirmatory and exploratory trails. In confirmatory 
trail, the selection of hypothesis is information 
dependent, although this study is also have clear 
objectives. These trails explore the doses of resultant 
studies and supply is also have clear objectives. These 
trails explore the doses of resultant studies and supply a 
basis for substantiating study style. A confirmatory trail 
may be a well controlled study within which the 
hypothesis of interest is predefined and is meant to 
supply within which the hypothesis of interest is 
predefined and is meant to supply onerous proof in 
support of claims that have clinical edges. A 
confirmatory trail is a smaller amount at risk of bias and 
more robust. Atherosclerotic cardiovascular disorder is 
that the leading cause to death in ladies within the 
United States and in most of the developed countries. 
Confirmatory cardiovascular clinical trial would be a 
multicentre, double-blind, randomised, parallel study of 
10,000 patients to check whether or not a replacement 
treatment compared with placebo reduces the incidence 
of the combined terminus of coronary death and nonfatal 
myocardial infraction in treatment of menoposal women 
in danger for coronary death. 
CLINICAL TRAIL: 
Objective: 
Clinical trial consists of two types of objectives which are 
primary and secondary. Primary objective is the most 
crucial question to answer at the end of the trail that 
shows the efficiency of the study. The primary objective 
is directly related to hypothesis of interest in a 
confirmatory trail. Based on safety and efficacy of the 
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intervention, secondary objective deals with the other 
related or unrelated questions. As mentioned earlier the 
primary objective is compared with the effect of the 
treatment with placebo on secondary death and nonfatal 
myocardial infarction. There could be several secondary 
objectives like stroke, test the effect of treatment on 
myocardial revascularization, and long-term safety.[1]    
Outcome measures: 
The ultimate goal of the clinical trial is to assess the 
effect of treatment on the outcomes which may be direct 
or indirect measurement of a clinical effect in a single, 
adequate, well-controlled clinical trial. Generally only 
one primary outcome will be there for primary objects 
which are used to test the intervention whether it is 
superior or inferior when compared to a comparative 
agent. The outcomes should be selected prospectively. 
Primary endpoint: 
Primary endpoint is an outcome which is related to the 
selected primary objective of the study and the size of 
the trail is also based on that. The primary endpoint in 
our earlier example is combined endpoint of coronary 
death and nonfatal myocardial infarction.  
Secondary endpoint: 
The secondary endpoint is the result which may or may 
not relate to primary objective of the study, which is only 
related to secondary objectives but they support the 
primary variables of the study. The secondary variable 
can be a time to an event, incidence rate of an event or 
continuous variable related to efficacy or safety. The 
secondary endpoint in the previous example are stroke, 
test the effect of treatment on myocardial 
revascularization, long-term safety.    
The primary and secondary endpoints can be clinical, 
surrogate, economic, global which are related to primary 
and secondary hypothesis. The design should be chosen 
adequately to reflect the objectives, appropriate primary, 
secondary, and global variables. 
Clinical endpoint: 
Clinical endpoint is a clear, appropriate outcome that can 
be objectively assessed without the judgement of the 
investigator. Nonfatal myocardial infarction is an 
example of an objective endpoint in contrast to a 
subjective endpoint, eg., relief of symptoms or severity of 
symptoms. The clinical endpoint is to be selected that 
can be reasonably and reliably assessed and can answer 
the primary objectives. Sometimes it is difficult to 
achieve both aims, so in such clinical judgement is 
required. Sometimes two different clinically meaningful 
endpoints can cross substantiate a claim for the effect of 
each outcome, so any definitions used to characterize the 
primary outcomes measure should be explained clearly.  
Surrogate endpoint: 
This is the endpoint that provides an indirect 
measurement of a clinical effect when measuring the 
outcome directly is not possible, as it require large 
sample size, long duration, and cost. Changes that are 
induced by the surrogate variables are expected to 
reflect changes in a clinical outcomes. For example 
surrogate variables might include biochemical markers 
of cardiovascular disease such as low density lipoprotein 
cholesterol, total cholesterol instead of myocardial 
infarction.[2] 
Economic endpoint: 
Several measurements regarding a subjects use of health 
care, cost of hospitilization, etc are considered as 
economic endpoints. The evaluation of subjects health 
has become more crucial in recent times. Subjective 
measures of health status are based on the quality of life 
scores of subjects performance, daily activity, mood etc. 
The overall score from these measurements can be 
analysed for treatment comparison. 
Global Assessment Variables: 
These variables measure the overall safety and efficacy 
of an intervention. These are generally based on rating 
scales. From these variables the idea of risk benefit 
profile of an intervention can be assessed, which helps 
the investigative physician to balance the safety and 
efficacy of the intervention and decide on treating 
subjects by weighing its risk and benefit outcomes.  
Medical issues: 
The outcome measures chosen to evaluate the efficacy or 
the primary objective depend on a number of factors, 
including; 
 Knowledge of adverse effects of closely related 
drugs 
 Information from non clinical or earlier clinical 
trails 
 The types of subjects to be enrolled 
Pharmacodynamic or pharmacokinetic properties of the 
treatment 
The endpoint should be capable of unbiased assessment. 
To have unbiased assessment of the endpoints, studies 
should be blinded. The instrument used to assess the 
primary variable should be reliable and adequately 
sensitive to detect any real change in the subject. The 
responsible variable should be measured for all subjects. 
The assessments of the response should be selected as 
standard, widely used, and recognised. 
Statistical Issues: 
The sample size and power calculation for a study should 
be based on the primary endpoint. The endpoint could be 
impedance rate of an event or time to an event. 
Distribution of events or frequency of episodes can be 
occurred in this case as re-occurrence of the primary 
event can occur. The investigator has to follow subject 
for a subsequent primary variable or subsequent 
response variable though subject participation ends as 
the primary subject. The subject must be followed, 
because he or she is at risk for the primary variable, if a  
secondary variable occur first.[3] 
If the subjects are lost to follow up, sometimes loss of 
statistical analysis for primary or secondary variables 
are based on the intent to treat principle of all 
randomised subjects, it is important to have complete 
information as the long term studies. Sometimes post 
hoc analysis based on a subject of randomised 
population are examined, for example the effect of an 
intervention for reducing the rate  of occurrence of 
myocardial infraction in the diabetic population, in some 
whether the treatment is more effective in the diabetic 
subjects or, irrespective of the population, the treatment 
effect is same. To obtain odds difference in proportions, 
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and time to an event data, it can be analysed by using 
binary data.  
Combined endpoints:  
Large sample size or a long study needed to have 
adequately power to detect a treatment when primary 
outcome measure occurs very frequently.  In this 
situation, combined endpoints are considered to enable 
the detection of treatment difference with smaller or 
shorter study duration. This combined endpoint has a 
meaningful clinical interpretation which combines more 
than one measurement related to practical object. 
Answering a question relating to the blind endpoint that 
only one event per subject should be counted, and also a 
hierarchy of each component shown be placed are 
improved. In addition, a combined endpoint could be 
considered in order to achieve more power to perform 
subgroup analyses.[4] 
Multiple Endpoint: 
Multiple endpoint are different clinical events that 
reflect a common mechanism of action because of the 
intervention. Sometimes it is important to have more 
than one primary variable when the investigator cannot 
state which of several variable addresses the primary 
objective of the study. Use of multiple endpoints will 
result in an increased probability of having false possible 
results. Nominal p value for each variable will be 
computed if more than one response variable is 
chosen.[5] Benferroni or similar adjustment methods can 
be used, if one of the multiple variables is of most 
importance and is most impacted by the intervention. 
Adjustment is not necessary if the intervention affects all 
the variables the same way, although the effects on the 
type 2 error and the sample size should be evaluated.[6]       
Clinical vs Surrogate endpoints: 
Clinical trials with a clinical endpoint are usually longer 
in duration, to determine an extended exposure of the 
treatment. These trails involve a large number of 
subjects as it drives the calculation of the sample size. 
The surrogate endpoint can replace the true clinical 
endpoint because it will often results in a shorter 
duration and the smaller sample size of the trail, as it is 
continuous nature of the data. The surrogate variables 
tend to change earlier in the study and the 
measurements can be taken at several time point, so the 
duration of the trail can be reduced.  
While choosing the surrogate variables, there are certain 
important things to consider: 
 Variables should be previously proven in literature 
to be highly correlated with the clinical endpoint. 
 The selected variables should be accepted by the 
regulatory authorities and medical community. 
 Selected variable should be reliably and accurately 
measured. 
 Invasive procedures should be avoided because 
they may result in high discontinuation rates. 
According to Prentice, a valid surrogate variable should 
be correlated with the clinical endpoint and should 
capture fully the treatments aggregate effect on the 
clinical endpoint.[7] 
Statistical Consideration of Surrogate Endpoints: 
Myocardial infarction is the clinical endpoint in a 
cardiovascular trail, LDL cholesterol is a surrogate 
endpoint. Comparison can be done by using change or 
percentage change, slopes throughout the interval and 
treatments based on repeated measures data are 
analysed at the beginning or end of the study. 
Responder Variable: 
When a continuous response variable is transformed to a 
binary or a categorical variable it can be interpreted as a 
responder variable. For example, the original continuous 
variable percentage change in LDL cholesterol can be 
modified to binary variables that takes two values: 1, of 
the percentage change in LDL is less than 0; 0, if the 
percentage change in LDL is greater than or equal to 0. 
The disadvantage in creating this responder variable is 
that not all the information is used in the analyses, which 
results in loss of power.[7]  
CONCLUSION:  
Clinical endpoints are regarded as a means to assess 
treatment in terms of feeling, functioning and survival of a 
patient. The endpoints reported should be clear relevant to 
the disease, condition, complaint or process of interest as 
well as the aim of treatment. Clinical endpoint should be 
reproducible and valid. The resultant endpoint will allow for 
comparisons across studies. A valid endpoint can evaluate 
what was intended to be evaluate. Reports of clinical 
endpoints should be interpreted in terms of reproducibility, 
validity, and statistical and clinical relevance. Endpoint 
evaluation by the patient, investigator or treating physician 
should ideally be done in a blinded fashion.   
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